Table 2. Treatment characteristics and response according to RECIST 1.1 for all patients (left column), KRAS-mutations (second column from left side), KRAS subgroups (third column from left side) and TP53 mutations (right column).
| Variable | All patients (n=119) | KRASmut (n=62) | KRASwt (n=57) | P value | KRASG12C (n=32) | KRASother (n=30) | P value | TP53mut (n=56) | TP53wt (n=63) | P value |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycles administered, n [range] | 10 [1–58] | 11 [1–45] | 8 [1–58] | 0.19 | 20 [1–38] | 9 [1–45] | 0.05* | 11 [1–43] | 9 [1–58] | 0.95 |
| Follow-Up, months (median, 95% CI) | 26.4 (24.3–28.5) | 28.9 (26.1–31.6) | 23.0 (19.9–26.1) | 0.05* | 26.9 (23.6–30.1) | 30.7 (27.3–34.2) | 0.18 | 23.7 (9.8–27.5) | 28.0 (23.8–32.1) | 0.07 |
| Duration of treatment, months (median, 95% CI) | 8.2 (5.5–11.0) | 11.2 (6.2–16.2) | 6.2 (2.1–10.3) | 0.20 | 20.0 (12.3–27.6) | 7.6 (4.7–10.5) | 0.03* | 7.2 (4.8–9.6) | 10.0 (3.4–16.7) | 0.51 |
| Therapy ongoing, n (%) | 21 (17.6) | 11 (17.7) | 10 (17.5) | 0.98 | 9 (28.1) | 2 (6.7) | 0.03* | 14 (25.0) | 7 (11.1) | 0.06 |
| RECIST-evaluation available, n (%) | 105 (88.2) | 55 (88.7) | 50 (87.7) | 1.0 | 30 (93.8) | 25 (83.3) | 0.20 | 50 (89.3) | 55 (87.3) | 0.78 |
| ORR, % [95% CI] | 48.6 [39–58] | 50.9 [36–64] | 46.0 [32–60] | 0.62 | 63.3 [47–80] | 36.0 [20–56] | 0.05* | 52.0 [38–66] | 45.5 [33–58] | 0.51 |
| DCR, % [95% CI] | 79.0 [71–86] | 83.6 [73–93] | 74.0 [62–86] | 0.23 | 86.7 [73–97] | 80.0 [64–92] | 0.51 | 76.0 [64–88] | 81.8 [71–91] | 0.47 |